Besifloxacin

Generic Name
Besifloxacin
Brand Names
Besivance
Drug Type
Small Molecule
Chemical Formula
C19H21ClFN3O3
CAS Number
141388-76-3
Unique Ingredient Identifier
BFE2NBZ7NX
Background

Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

Indication

Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*

Associated Conditions
Bacterial Conjunctivitis
Associated Therapies
-
Clinical Trials
Related News

Besifloxacin in Bacterial Keratitis

Not Applicable
Completed
Conditions
Bacterial Keratitis
Interventions
Drug: Besifloxacin
Drug: Tobramycin and Cefazolin
First Posted Date
2015-07-14
Last Posted Date
2023-10-19
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Target Recruit Count
32
Registration Number
NCT02497365
Locations
🇨🇦

McGill Academic Eye Center, Montreal, Quebec, Canada

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Phase 3
Terminated
Conditions
Bacterial Conjunctivitis
Interventions
Drug: Vehicle
Drug: Besifloxacin
First Posted Date
2012-12-04
Last Posted Date
2014-10-01
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
136
Registration Number
NCT01740388
Locations
🇺🇸

Bausch & Lomb Incorporated, Rochester, New York, United States

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

Phase 4
Completed
Conditions
Corneal Health
Cataract Surgery
Interventions
Drug: vigamox
Drug: besivance
First Posted Date
2011-10-19
Last Posted Date
2011-10-19
Lead Sponsor
Ophthalmology Consultants, Ltd.
Target Recruit Count
60
Registration Number
NCT01455233
Locations
🇺🇸

Ophthalmology Associates, St. Louis, Missouri, United States

🇺🇸

Ophthalmology Consultants, Ltd, St. Louis, Missouri, United States

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Phase 3
Terminated
Conditions
Bacterial Conjunctivitis
Interventions
Drug: Besivance
Drug: Gatifloxacin
First Posted Date
2011-04-06
Last Posted Date
2014-09-03
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
33
Registration Number
NCT01330355
Locations
🇺🇸

Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

Phase 4
Completed
Conditions
Cataracts
Interventions
Drug: Moxifloxacin
Drug: besifloxacin
First Posted Date
2011-02-15
Last Posted Date
2020-12-22
Lead Sponsor
Frank A. Bucci, Jr., M.D.
Target Recruit Count
120
Registration Number
NCT01296191
Locations
🇺🇸

Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Phase 3
Completed
Conditions
Bacterial Conjunctivitis
Interventions
Drug: Vehicle
Drug: Besivance
First Posted Date
2010-08-05
Last Posted Date
2013-05-01
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
518
Registration Number
NCT01175590
Locations
🇺🇸

Bausch & Lomb, Inc., Rochester, New York, United States

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

First Posted Date
2009-09-09
Last Posted Date
2012-03-29
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
474
Registration Number
NCT00972777
Locations
🇺🇸

Bausch & Lomb Incorporated, Rochester, New York, United States

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

First Posted Date
2009-05-21
Last Posted Date
2011-12-09
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
119
Registration Number
NCT00905762
Locations
🇺🇸

Bausch & Lomb Incorporated, Rochester, New York, United States

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

First Posted Date
2006-07-04
Last Posted Date
2015-03-24
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
1161
Registration Number
NCT00348348
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy